SM-7368
Based on 1 Customer Validation
SM-7368 is a potent NF-kB inhibitor that targets downstream of MAPK p38 activation. SM-7368 inhibits TNF-α-induced MMP-9 upregulation. SM-7368 can be used for the research of chemotherapies targeting TNF-α-mediated tumor invasion and metastasis .
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.77%
- CAS No.: 380623-76-7
- Formule: C10H5ClN4O5S
- Masse moléculaire:328.69
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-13982
JSH-23
-
HY-10496
SC75741
-
HY-32721
Neratinib
-
HY-B0497
Niclosamide
-
HY-130253
IRAK4-IN-6
-
HY-N0274
Caffeic acid phenethyl ester
-
HY-32718
Pelitinib
-
HY-N2065
Withaferin A
-
HY-18738
Pyrrolidinedithiocarbamate ammonium
-
HY-N0274R
Caffeic acid phenethyl ester (Standard)
-
HY-18935A
CBL0137 hydrochloride
-
HY-138295
KRAS inhibitor-10
Activité biologique
|
NF-κB |
MMP-9 |
p38 MAP kinase |
SM-7368 (5 μM) targets downstream of MAPK p38 activation in the human colon derived crypt like HT-29 and Caco-2 epithelial cell lines[1].
SM-7368 inhibits TNF-α-induced MMP-9 upregulation in a concentration-dependent manner and shows maximal activity at 10 μM. SM-7368 inhibits TNF-α-induced MMP-9 mRNA transcript accumulation and protein expression. SM-7368 strongly inhibits TNF-α-induced NF-κB activity but not AP-1 activity. SM-7368 strongly inhibits the TNF-α-induced invasion of HT1080 human fibrosarcoma cell line[2].
SM-7368 (10-25 μM) greatly inhibits TNF-α (20 ng/mL)-induced MMP-9 upregulation. 10 μM of SM-7368 almost completely abrogates this upregulation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HT1080 human fibrosarcoma cells
-
Concentration:0, 1, 5, 10, 15, 20, and 25 μM
-
Incubation Time:24 hours
-
Result:Greatly inhibited TNF-α (20 ng/mL)-induced MMP-9 upregulation in a concentration-dependent manner.
Chemical Information
-
CAS No. 380623-76-7
-
Appearance Solid
-
Masse moléculaire 328.69
-
Formule C10H5ClN4O5S
-
Color Off-white to light yellow
-
SMILES
ClC1=C(C=CC(C(NC2=NC=C(S2)[N+]([O-])=O)=O)=C1)[N+]([O-])=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 50 mg/mL (152.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.33 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Sabine Kuntz, et al. Carbonyl compounds methylglyoxal and glyoxal affect interleukin-8 secretion in intestinal cells by superoxide anion generation and activation of MAPK p38. Mol Nutr Food Res. 2010 Oct;54(10):1458-67. [Content Brief]
[2]. Ha Young Lee, et al. A small compound that inhibits tumor necrosis factor-alpha-induced matrix metalloproteinase-9 upregulation. Biochem Biophys Res Commun. 2005 Oct 21;336(2):716-22. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0424 mL | 15.2119 mL | 30.4238 mL | 76.0595 mL |
| 5 mM | 0.6085 mL | 3.0424 mL | 6.0848 mL | 15.2119 mL | |
| 10 mM | 0.3042 mL | 1.5212 mL | 3.0424 mL | 7.6060 mL | |
| 15 mM | 0.2028 mL | 1.0141 mL | 2.0283 mL | 5.0706 mL | |
| 20 mM | 0.1521 mL | 0.7606 mL | 1.5212 mL | 3.8030 mL | |
| 25 mM | 0.1217 mL | 0.6085 mL | 1.2170 mL | 3.0424 mL | |
| 30 mM | 0.1014 mL | 0.5071 mL | 1.0141 mL | 2.5353 mL | |
| 40 mM | 0.0761 mL | 0.3803 mL | 0.7606 mL | 1.9015 mL | |
| 50 mM | 0.0608 mL | 0.3042 mL | 0.6085 mL | 1.5212 mL | |
| 60 mM | 0.0507 mL | 0.2535 mL | 0.5071 mL | 1.2677 mL | |
| 80 mM | 0.0380 mL | 0.1901 mL | 0.3803 mL | 0.9507 mL | |
| 100 mM | 0.0304 mL | 0.1521 mL | 0.3042 mL | 0.7606 mL |
SM-7368 Related Classifications
HY-116626 Related Classifications
Powered by Bioz